Researchers at Cambridge University in the UK are trialling an artificial intelligence system that they think could spot the signs of dementia after a single brain scan.
The FDA's approval of Biogen's Aduhelm for Alzheimer's disease has emboldened Eli Lilly to move forward plans to file its own candidate donanemab later this year, although it acknowledges i
Biogen and partner Eisai have said they will run a large-scale observational study of Alzheimer's drug Aduhelm in the US to build evidence for the drug's efficacy following its controversia
With a string of new drugs for Alzheimer's disease making their way through late-stage clinical testing, the demand for suitable subjects to enrol into trials is running at an all-time high
Biogen has reported $2m in sales for newly-launched Alzheimer's therapy Aduhelm that came in below its expectations, prompting the company to issue a rebuke to what it says is "extensive mi
Phase 3 results with Roche's amyloid-targeting Alzheimer's drug gantenerumab may not be due until the second half of last year, but the company is already in discussions with the FDA about
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.